In addition to their CD4+ T cell activating capacities, all three subsets can cross-present exogenous antigens for cognate restimulation of previously activated CD8+ T cells [10–14], making them promising candidates for DC-based vaccination strategies against cancer. Here, CD8A is linked to cancer.